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Aim Low-molecular-weight heparins (LMWH) or fondaparinux (fonda) appear to be as effective and safe as intravenous unfractionated heparin 
(UFH) in pts with acute pulmonary embolism (PE). UFH is the only anticoagulant treatment recommended in association with thrombolytic agents in 
this setting. No data are available on the efficacy and safety of enoxaparin (enox) or fonda as adjunctive therapy to thrombolysis in patients with PE.
Methods Prospective, single-center registry of confirmed intermediate to high risk PE pts. We used a combined in-hospital endpoint defined as 
death, recurrent PE, or major bleeding. To adjust for potential bias, we used a propensity score by logistic regression, corresponding to the predicted 
probability that patients were treated by UFH, vs enox or fonda. Secondary endpoints were residual pulmonary vascular obstruction (RPVO) as 
assessed by perfusion lung scan at discharge and 6 months.
Results Among 951 pts submitted to thrombolysis from 1995-2010, 637 received UFH, 220 enox, and 64 fonda. Baseline characteristics were 
similar. Results are reported in the table. After adjusting on propensity score, there was no significant difference in terms of death, recurrent PE, 
major bleeding or combined endpoint, or in RPVO at discharge and 6 months follow-up. 
Conclusion Our data suggest that enox and fonda procure adequate efficacy and tolerability vs standard current therapy in combination with 
thrombolysis in high to intermediate risk PE.
UFH (N=637) Enox (n=220) Fonda (N=64) P Non adjusted
OR (95%CI) UFH vs Enox 
adjusted
OR (95%CI) UFH vs Fonda 
adjusted
In-hospital death 54 (8.5%) 19 (8.6%) 1 (1.6%) 0.14 0.22 (0.03-1.67) 0.17 (0.02-1.49
Recurrent PE 35 (5.5%) 6 (2.7%) 2 (3.1%) 0.20 1.49 (0.28-7.87) 0.71 (0.16-3.2_
Major bleeding 64 (10.1%) 29 (13.2%) 6 (9.4%) 0.40 0.69 (0.22-2.24) 0.52 (0.16-3.2)
Combined endpoint 110 (17%) 36 (16.4%) 7 (10.9%) 0.43 0.85 (0.37-1.97) 0.80 (0.36-1.79)
